Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir + Sofosbuvir + Ribavirin in Genotype 3 HCV Cirrhosis
NCT02673489Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of daclatasvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Started Mar 2016; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02673489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02673489.